Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Daratumumab (Primary) ; T cell replacement therapy (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 21 Aug 2019 Status changed from not yet recruiting to recruiting.
- 29 Jul 2019 Planned initiation date changed from 28 Feb 2019 to 1 Sep 2019.
- 29 Jan 2019 Planned initiation date changed from 31 Dec 2018 to 28 Feb 2019.